文献速递关节外科

全膝关节置换术前收肌管阻滞中使用脂质体布比卡因可改善术后结局:一项随机对照试验

Liposomal Bupivacaine in Adductor Canal Blocks Before Total Knee Arthroplasty Leads to Improved Postoperative Outcomes: A Randomized Controlled Trial.
PubMed 文献 · J Arthroplasty · 2022-03-26

该前瞻性双盲随机对照试验纳入100例单侧初次全膝关节置换术患者,比较收肌管阻滞中使用脂质体布比卡因(Exparel)与罗哌卡因的效果。Exparel组住院时间更短(36.3 vs 49.7小时,P<.01),术后各时间点疼痛数字评分改善更明显,住院阿片类药物用量更少(40.9 vs 47.3 MME/d,P=.04),WOMAC评分改善更优。

要点

  • Exparel组住院时间36.3小时 vs 对照组49.7小时(P<.01)。
  • Exparel组住院阿片用量40.9 MME/d vs 对照组47.3 MME/d(P=.04)。
  • Exparel组术后各时间点疼痛评分改善及多数时间点WOMAC评分改善更优(P<.05)。

核心结论

  • Exparel外周区域神经阻滞可降低疼痛水平、缩短住院时间、减少住院阿片类药物用量并改善WOMAC评分。
  • Exparel可安全用于全膝关节置换术前收肌管阻滞,以帮助控制术后疼痛并缩短住院时间。

研究设计与样本

  • 2020年4月至2021年9月开展的前瞻性、双盲随机对照试验,计划纳入147例接受单侧初次全膝关节置换术的患者。
  • 每例患者均接受使用罗哌卡因的iPACK阻滞,并随机加用Exparel或罗哌卡因的收肌管阻滞。
  • 最终纳入100例患者(每组50例),收集人口学信息、住院信息、术后阿片类药物用量及WOMAC问卷评分。

主要发现

  • Exparel组住院时间较对照组缩短(36.3 vs 49.7小时,P<.01)。
  • Exparel组在所有术后时间点报告的疼痛数字评分改善程度均增加。
  • Exparel组住院阿片类药物用量较对照组减少(40.9 vs 47.3 MME/d,P=.04),但门诊阿片类药物用量相似(33.4 vs 32.1 MME/d,P=.351)。
  • Exparel组在大多数时间点所有WOMAC子评分及总评分改善均优于对照组(P<.05)。

关键数值与推荐

  • Exparel组住院时间36.3小时 vs 对照组49.7小时(P<.01)。
  • Exparel组住院阿片用量40.9 MME/d vs 对照组47.3 MME/d(P=.04)。
  • Exparel组门诊阿片用量33.4 MME/d vs 对照组32.1 MME/d(P=.351)。

临床怎么用

  • 作者认为Exparel可安全用于全膝关节置换术前收肌管阻滞,以帮助控制术后疼痛并缩短住院时间。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study compares the use of liposomal bupivacaine (Exparel) versus ropivacaine in adductor canal blocks (ACB) before total knee arthroplasties (TKAs). METHODS: From the months of April 2020 to September 2021, 147 patients undergoing unilateral primary TKA were asked to participate in this prospective, double-blinded randomized controlled trial. Each patient received an iPACK block utilizing ropivacaine and was additionally randomized to receive an ACB with Exparel or Ropivacaine. For each patient, demographic information, inpatient hospital information, postoperative opioid use, and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) questionnaire scores were collected. RESULTS: Overall, 100 patients were included (50 in each cohort). The Exparel group had a lower hospital length of stay compared to the Control group (36.3 vs 49.7 hours, P < .01). Patients in the Exparel group reported an increased amount of Numerical Rating Scale pain score improvement at all postoperative timepoints. These patients also used a lower amount of inpatient opioids (40.9 vs 47.3 MME/d, P = .04) but a similar amount of outpatient opioids (33.4 vs 32.1 MME/d, P = .351). Finally, the Exparel group had increased improvements in all WOMAC subscores and total scores at most timepoints compared to the Control group (P < .05). CONCLUSION: Exparel peripheral regional nerve blocks lead to decreases in pain levels, shorter hospital lengths of stay, inpatient opioid usage, and improved WOMAC scores. Exparel can be safely used in ACB blocks before TKA to help in controlling postoperative pain and decrease length of stay.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Malige A, Pellegrino AN, Kunkle K, et al. Liposomal Bupivacaine in Adductor Canal Blocks Before Total Knee Arthroplasty Leads to Improved Postoperative Outcomes: A Randomized Controlled Trial. J Arthroplasty. 2022. PMID: 35351553. doi:10.1016/j.arth.2022.03.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。